Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study.
mTOR inhibitors avoid calcineurin nephrotoxicity, but sirolimus de novo is associated with unacceptable side effects and higher rejection rates. We have investigated a modified strategy: alemtuzumab induction with tacrolimus and mycophenolate maintenance, switching from tacrolimus to sirolimus at 6...
| 主要な著者: | , , , , , , , , |
|---|---|
| フォーマット: | Conference item |
| 出版事項: |
2014
|